Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis

Table 6

Univariate and multivariate analysis of survival outcomes in overall GCLM and of the subgroup of serum AFP ≥ 20 ng/ml.

	GCLM with serum AFP ≥ 20 ng/ml ()					Overall GCLM ()
	Univariate analysis (KM)		Multivariate analysis (Cox)			Univariate analysis (KM)		Multivariate analysis (Cox)
Variable	mOS (m)	value	HR	95% CI	value	mOS (m)	value	HR	95%CI	value
Gender
Male	9.9	0.608				14.1	0.609
Female	15.1					14.8
Age
≤65	9.2	0.773				14.8	0.379
>65	11.3					14.9
ECOG
0-1	9.2	0.095				16.5	0.227
2-3	11.3					14.5
Disease status
LM after radical resection	10.4	0.411				19.3	0.046	0.700	0.359–1.364	0.295
LM at first diagnosis	10.9					14.5
Primary lesion site
GEJ	14.9	0.103				15.2	0.600
Non-GEJ	9.4					14.5
Histologic classification
Intestinal	12.7	0.757				16.1	0.021	0.558	0.370–0.840	0.005
Nonintestinal	12.0					11.2
HER2 status
Positive	12.7	0.888				17.3	0.293
Negative	15.1					15.2
Extrahepatic M
Present	10.4	0.116				14.6	0.952
Absent	12.2					15.5
Peritoneal M
Present	4.6	<0.001	4.411	1.817–10.712	0.001	10.8	0.001	1.953	1.105–3.451	0.021
Absent	11.3					15.4
LM numbers
1–3	17.6	0.115				19.5	0.002	0.416	0.236–0.733	0.002
>3	9.9					12.7
First-line chemo regimen
Doublet regimen	9.9	0.157				14.9	0.816
Triplet regimen	37.6					17.3
Response to first-line chemo
PR	15.4	0.017	0.328	0.173–0.624	0.001	19.2	<0.001	0.506	0.334–0.768	0.001
SD + PD	9.4					11.4
Local treatment for LM
Yes	19.2	0.003	0.356	0.179–0.710	0.003	20.8	<0.001	0.623	0.394–0.986	0.043
No	8.4					12.4
Serum AFP level (ng/ml)
≥20 ng/ml						10.9	0.004	1.553	1.006–2.397	0.047
<20 ng/ml						15.7